These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 29514023)

  • 1. Balancing Safety and Innovation for Cell-Based Regenerative Medicine.
    Marks P; Gottlieb S
    N Engl J Med; 2018 Mar; 378(10):954-959. PubMed ID: 29514023
    [No Abstract]   [Full Text] [Related]  

  • 2. Rejuvenating Regenerative Medicine Regulation.
    Charo RA; Sipp D
    N Engl J Med; 2018 Feb; 378(6):504-505. PubMed ID: 29320637
    [No Abstract]   [Full Text] [Related]  

  • 3. The government's role in advancing regenerative medicine and tissue engineering - science, safety, and ethics.
    Smith DS
    Periodontol 2000; 2006; 41():16-29. PubMed ID: 16686924
    [No Abstract]   [Full Text] [Related]  

  • 4. Informed consent and living human cells.
    Maloney DM
    Hum Res Rep; 2002 Jul; 17(7):3. PubMed ID: 12731490
    [No Abstract]   [Full Text] [Related]  

  • 5. Balancing Safety and Efficacy With Early Availability in the Regulation of Regenerative Medicine Product.
    Fujiwara Y; Maruyama Y; Honda F
    Clin Pharmacol Ther; 2021 May; 109(5):1182-1185. PubMed ID: 32979224
    [No Abstract]   [Full Text] [Related]  

  • 6. Is the FDA regulating the practice of medicine?
    Aicher RH
    Aesthet Surg J; 2013 Mar; 33(3):452-5. PubMed ID: 23515389
    [No Abstract]   [Full Text] [Related]  

  • 7. Cells as drugs?: regulating the future of medicine.
    Pivarnik G
    Am J Law Med; 2014; 40(2-3):298-321. PubMed ID: 25211998
    [No Abstract]   [Full Text] [Related]  

  • 8. Regulation of Regenerative Medicine Products.
    Gee AP
    Adv Exp Med Biol; 2018; 1098():189-198. PubMed ID: 30238372
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A RAT by Another Name: 21
    Riley MF
    Am J Law Med; 2018 May; 44(2-3):291-308. PubMed ID: 30106653
    [No Abstract]   [Full Text] [Related]  

  • 10. The implications of "advanced therapies" regulation.
    Sethe SC
    Rejuvenation Res; 2010; 13(2-3):327-8. PubMed ID: 20462386
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Governmental Regulations and Increasing Food and Drug Administration Oversight of Regenerative Medicine Products: What's New in 2020?
    Fang WH; Vangsness CT
    Arthroscopy; 2020 Oct; 36(10):2765-2770. PubMed ID: 32442713
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FDA faces regulatory challenges with new approaches to medicine.
    Roehr B
    BMJ; 2014 Feb; 348():g1530. PubMed ID: 24531207
    [No Abstract]   [Full Text] [Related]  

  • 13. Cell Therapy Regulatory Toolkit: an online regulatory resource.
    Culme-Seymour EJ; Davies JL; Hitchcock J; Mason J; Carpenter MK; Mason C
    Regen Med; 2015; 10(5):531-4. PubMed ID: 26237697
    [No Abstract]   [Full Text] [Related]  

  • 14. New Japanese initiatives on stem cell therapies.
    Konomi K; Tobita M; Kimura K; Sato D
    Cell Stem Cell; 2015 Apr; 16(4):350-2. PubMed ID: 25842974
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A strategic road map to filing a Biologics License Application for a pluripotent stem cell derived therapeutic product.
    Creasey AA; Stacey G; Bharti K; Sato Y; Lubiniecki A
    Biologicals; 2019 May; 59():68-71. PubMed ID: 31053443
    [No Abstract]   [Full Text] [Related]  

  • 16. The Food and Drug Administration, regenerative sciences, and the regulation of autologous stem cell therapies.
    von Tigerstrom B
    Food Drug Law J; 2011; 66(4):479-506, i. PubMed ID: 24505826
    [TBL] [Abstract][Full Text] [Related]  

  • 17. No need for more regulation: payors and their role in balancing the cost and safety considerations of off-label prescriptions.
    Todd AE
    Am J Law Med; 2011; 37(2-3):422-43. PubMed ID: 21847887
    [No Abstract]   [Full Text] [Related]  

  • 18. Medicine's Wild West--Unlicensed Stem-Cell Clinics in the United States.
    Taylor-Weiner H; Graff Zivin J
    N Engl J Med; 2015 Sep; 373(11):985-7. PubMed ID: 26352811
    [No Abstract]   [Full Text] [Related]  

  • 19. Mapping and driving the stem cell ecosystem.
    Knoepfler PS
    Regen Med; 2018 Oct; 13(7):845-858. PubMed ID: 30289055
    [TBL] [Abstract][Full Text] [Related]  

  • 20. US FDA outreach to the regenerative medicine community: challenges and opportunities.
    Whittlesey KJ; Witten C
    Regen Med; 2012 Jul; 7(4):595-603. PubMed ID: 22817631
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.